Prospective Study of Maple-Syrup-Urine Disease for the First Four Days of Life
- 9 December 1982
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 307 (24) , 1492-1495
- https://doi.org/10.1056/nejm198212093072405
Abstract
Maple-syrup-urine disease, also known as branched-chain ketoaciduria, results from a primary defect in oxidative decarboxylation of the ketoacids derived from the branched-chain amino acids leucine, isoleucine, and valine.1 Neonates with the most common form of this autosomal recessive disorder (classic maple-syrup-urine disease) appear normal at birth but usually become symptomatic by four or five days of age, with lethargy, poor appetite, vomiting, and alternating periods of hypertonicity and flaccidity. Progressive neurologic deterioration, seizures, coma, and acidosis ensue; death may occur within 10 to 14 days if the condition is untreated.2 Delay in diagnosis or improper treatment results in mental retardation . . .Keywords
This publication has 4 references indexed in Scilit:
- Activities of branched-chain 2-oxo acid dehydrogenase and its components in skin fibroblasts from normal and classical-maple-syrup-urine-disease subjectsBiochemical Journal, 1981
- Prospective Study of Early Neonatal Screening for PhenylketonuriaNew England Journal of Medicine, 1981
- A Comparison of the Effects of Intravenous Infusion of Individual Branched-Chain Amino Acids on Blood Amino Acid Levels in ManClinical Science, 1981
- Cord-blood tyrosine levels in the full-term phenylketonuric fetus and the "justification hypothesis".Proceedings of the National Academy of Sciences, 1980